N
Power Law company profile
Neumora Therapeutics
Biotech & Life Sciences · Waltham, United States · Founded 2020 · IPO 2023 Unicorn
Valuation
$282M
Market cap · Apr/2026
Global footprint
Where Neumora Therapeutics has talent and traffic
AI talent share
2.7%
of workforce is AI talent
(3 of 111 staff)
(3 of 111 staff)
Core AI00%
Other AI32.7%
Non-AI workforce10897.3%
Web traffic by country
11K
monthly visits
across markets
across markets
🇺🇸 United States49.1%
🇬🇧 United Kingdom16.4%
🇨🇦 Canada14.5%
🇪🇸 Spain11.8%
🇮🇳 India4.5%
Patent intelligence
$66M patent portfolio · 42 active families
Total estimated portfolio value via Dealroom Patent Intelligence (Patsnap), with quality scores compared against same-sector peers.
Estimated portfolio value
$66M
23.5% of market cap · 4.2× smaller than top peer Ascendis Pharma ($275M)
42 active patent families
Where Neumora Therapeutics innovates
Medicinal chemistryPharmacologyPharmaceutical medicineMedicineData science
Above peer median on Market
Quality vs same-sector peers
Neumora Therapeutics on the five Patsnap quality dimensions
Neumora Therapeutics in orange. Same-sector peers are the top filers by total patent value. All scores 0–100; higher is stronger.
Compare against
Patent quality scores (0–100)
Source: Dealroom Patent Intelligence · PatsnapTech-focus vs peers
Where Neumora Therapeutics concentrates inside the peer cluster
Axes are the most-shared Patsnap topics across Neumora Therapeutics and its top peers. Each polygon's reach on an axis = how prominent that topic is in that company's portfolio (#1 topic = 100, #10 = 10, absent = 0).
Compare against
Top-topic prominence (rank inverted, 0–100)
Source: Dealroom Patent Intelligence · Patsnap top-10 topics per companySee Neumora Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.